NCT02450331终止3 期
A Phase III, Open-Label, Multicenter, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Versus Observation as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Urothelial Carcinoma After Surgical Resection
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 入组人数
- 809
- 试验地点
- 186
- 主要终点
- Disease-Free Survival (DFS), as Assessed by Investigator
研究概览
简要总结
This Phase III, open-label, randomized, multicenter study is to evaluate the efficacy and safety of adjuvant treatment with atezolizumab compared with observation in participants with muscle-invasive UC who are at high risk for recurrence following resection. Eligible participants were randomized by a 1:1 ratio into atezolizumab group or control group.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed muscle-invasive UC (also termed transitional cell carcinoma) of the bladder or upper urinary tract (i.e., renal pelvis or ureters)
- •For participants treated with prior neoadjuvant chemotherapy: tumor stage of ypT2-4a or ypN+ (ypT2-4 or ypN+ for participants with upper urinary tract UC) and M0
- •For participants who have not received prior neoadjuvant chemotherapy: tumor stage of pT3-4a or pN+ (pT3-4 or pN+ for participants with upper urinary tract UC) and M0
- •Representative formalin-fixed paraffin-embedded tumor specimens from surgical resection (i.e., radical cystectomy, nephroureterectomy, or lymph node dissection) in paraffin blocks (blocks preferred) or at least 15 unstained slides, with an associated pathology report, for central testing and determined to be evaluable for tumor programmed death-ligand 1 (PD-L1) expression prior to study enrollment
- •Absence of residual disease and absence of metastasis, as confirmed by a negative baseline computed tomography (CT) or magnetic resonance imaging scan of the pelvis, abdomen, and chest no more than 4 weeks prior to randomization
- •Full recovery from cystectomy or nephroureterectomy within 14 weeks following surgery
- •Eastern Cooperative Oncology Group performance status of less than or equal to (</=) 2
- •Life expectancy greater than or equal to (>/=) 12 weeks
- •Adequate hematologic and end-organ function
- •For women who are not postmenopausal or surgically sterile: agreement to remain abstinent or use contraceptive methods that result in a failure rate of less than (<) 1 percent (%) per year during the treatment period and for at least 5 months after the last dose of atezolizumab
排除标准
- •Any approved anti-cancer therapy within 3 weeks prior to initiation of study treatment
- •Adjuvant chemotherapy or radiation therapy for UC following surgical resection
- •Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 28 days or five half-lives of the drug prior to enrollment
- •Malignancies other than UC within 5 years prior to Cycle 1, Day 1
- •Pregnancy or breastfeeding
- •Significant cardiovascular disease
- •Severe infections within 4 weeks prior to Cycle 1, Day 1
- •Major surgical procedure other than for diagnosis within 28 days prior to Cycle 1, Day 1
- •History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
- •Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation
- •History of autoimmune disease
- •Prior allogeneic stem cell or solid organ transplant
- •History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan
- •Positive test for human immunodeficiency virus and/or active hepatitis B or hepatitis C or tuberculosis
- •Administration of a live, attenuated vaccine within 4 weeks before Cycle 1 Day 1
- •Prior treatment with cluster of differentiation 137 (CD137) agonists or immune checkpoint blockade therapies, including anti-CD40, anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4), anti-programmed death-1 (anti-PD-1), and anti-PD-L1 therapeutic antibodies
研究组 & 干预措施
Atezolizumab
Experimental
Participants will receive intravenous (IV) atezolizumab on Day 1 of each 21-day cycle for 16 cycles (up to 1 year).
干预措施: Atezolizumab (Drug)
结局指标
主要结局
Disease-Free Survival (DFS), as Assessed by Investigator
时间窗: Randomization up to first occurrence of DFS event (up to approximately 50 months)
DFS is defined as the time from randomization to the time of first occurrence of a DFS event. DFS events include: local (pelvic) recurrence of UC (including soft tissue and regional lymph nodes); urinary tract recurrence of UC (including all pathological stages and grades); distant metastasis of UC; or death from any cause. Tumor assessment will be performed using radiographic evaluations.
次要结局
- Overall Survival (OS)(Randomization until death due to any cause (up to approximately 80 months))
- Disease-Specific Survival (DSS), as Assessed by Investigator(Randomization until death due to UC (up to approximately 50 months))
- Distant Metastasis-Free Survival (DMFS)(Randomization up to diagnosis of distant metastases or death from any cause (up to approximately 50 months))
- Non-Urinary Tract Recurrence-Free Survival (NURFS)(Randomization up to time of first occurrence of a NURFS event (up to approximately 50 months))
- Percentage of Participants With Adverse Events (AEs)(Screening up to approximately 80 months)
- Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Atezolizumab(Baseline up to approximately 50 months)
- EuroQol 5-Dimension 5-Level (EQ-5D-5L) Visual Analogue Scale Score(Day 1 of Cycle 1 up to approximately 50 months (Cycle length = 21 days))
- Minimum Observed Serum Atezolizumab Concentration (Cmin)(Pre-dose (Hour 0) on Day 1 of Cycles 1, 2, 3, 4, every 8 cycles from Cycle 8, at treatment discontinuation, 120 days after treatment discontinuation (up to approximately 50 months))(Cycle length = 21 days))
- Maximum Observed Serum Atezolizumab Concentration (Cmax)(Day 1 of Cycle 1 (Cycle length = 21 days))
研究者
研究点 (186)
Loading locations...
相似试验
撤回
3 期
Efficacy and Safety Study of Formoterol/Fluticasone and Salmeterol/Fluticasone in Patients With Moderate-to-severe COPDChronic Obstructive Pulmonary DiseaseCOPDNCT01393145Ache Laboratorios Farmaceuticos S.A.
已完成
3 期
A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)Carcinoma, Non-Squamous Non-Small Cell LungNCT02367781Hoffmann-La Roche723
已完成
3 期
A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)Anaplastic Lymphoma Kinase-positive Non-small Cell Lung CancerNCT02838420Hoffmann-La Roche187
进行中（未招募）
3 期
Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic LeukemiaUntreated Chronic Lymphocytic LeukemiaNCT04075292AstraZeneca155
已完成
3 期
A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing ChemotherapyCarcinoma, Non-Small-Cell LungNCT02813785Hoffmann-La Roche565